Hmmm... my post didn't get moderated. I guess it's still okay to express one's opinion, good or bad. Now I know how Sam and Akki feel. If someone expresses a view that's not positive, they may get threatened with being reported to HC, ASX, ASIC etc.
Okay, I was a bit frustrated this morning having seen the announcement and I apologise if anyone thinks it was down-ramping or manipulative. Just to set the record straight, I am not down-ramping the company. I desperately want it to succeed as I'm heavily over-exposed but I want to see it managed in the best way for shareholders.
It's interesting that @Motors (who is very new to PER obviously) can make lots of ramping statements without ever being contradicted or moderated. For example, A$15m does not get you very far in the biotech world. It may pay for a couple of years of salaries, a modest R&D budget (tox, IND, manufacturing, QA etc work) and maybe a Phase 1 safety study. Then PER will come cap-in-hand for more money again which is standard practice for the small end of biotech town. Secondly, you are correct, JG can take PER and make it his own (if he hasn't already), just as he did with Novogen/Kazia. Maybe you should do some research before making these statements. They bring back some painful memories for the current and ex-Kazia shareholders.
Anyway, I did not mean any offence, just expressing my frustrations.
IMO GLTAH
PER Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)